NeuroSense Gains FDA Approval for Phase 3 ALS Trial

Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.

NeuroSense Therapeutics Ltd. announced on November 24, 2025, that it has received FDA clearance to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, for the treatment of ALS. This trial, named PARAGON, will be conducted in the U.S. and EU, involving 300 participants and aims to build on the promising results of the Phase 2b PARADIGM trial. The FDA’s clearance is a significant advancement for NeuroSense, potentially strengthening its position in the biotechnology industry and offering hope for ALS patients.

The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

Spark’s Take on NRSN Stock

According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.

Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.

To see Spark’s full report on NRSN stock, click here.

More about Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Parkinson’s disease. The company aims to address significant unmet medical needs by creating combined therapies targeting multiple pathways associated with these complex diseases.

Average Trading Volume: 605,623

Technical Sentiment Signal: Sell

Current Market Cap: $27.06M

For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.